Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

Henagliflozein and Metformin

Phase 3Small molecule

ZZhujiang Hospital

1

Indications

1

Total Trials

1

Active Trials

0

Competitors

Pipeline

Status by Indication[3][1]

Indication

NAFLDRecruiting

NAFLDPhase 3

Recruiting

Timeline

Expected Milestones

Q4 2026

Post-ApprovalRecruiting

NAFLD

NCT06449833

Clinical

Trials by Indication[1]

NAFLD1 trial

Effect of Henagliflozein on Hepatic Fat Content in Patients With T2DM and NAFLD

Recruiting·ZZhujiang Hospital·Phase 4·NCT06449833·100 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Henagliflozein and Metformin. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Henagliflozein and Metformin compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Henagliflozein and Metformin. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Zhujiang Hospital company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: ZZhujiang Hospital

Related News